Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.14 USD
-0.20 (-8.55%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.18 +0.04 (1.87%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Brokerage Reports
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 61 - 80 ( 118 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Developing Effective Antisense ssDNA Drugs Safe Enough for Combination Rx -Initiation of Coverage
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Prexigebersen Preclinical Cancer Model Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
1Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
4Q and Full-Year 2019 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Patient Dosing Commences in Amended Phase 2 Combo Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Prexigebersen Power; Initiating at Buy and $28 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q17 Financial Results; AML Interim Data Delayed; Reiterate Buy and Lowering Price Target to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q17 Financial Results Reported; AML Interim Data in 2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q17 Financial Results Reported; AML Interim Data in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
New Composition of Matter Patent Allowed; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
New Composition of Matter Patent Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2017 1Q Financial Results; Phase 2 AML Trial Interim Analysis On Track; Reiterate Buy
Provider: Rodman & Renshaw, Co.